Literature DB >> 26793611

Molecular Targeting of Her-2/neu Protein Is Not Recommended as an Adjuvant Therapy in Oral Squamous Cell Carcinoma and Oral Lichen Planus.

Maryam Kouhsoltani1, Amirala Aghbali1, Behrooz Shokoohi2, Ronak Ahmadzadeh3.   

Abstract

PURPOSE: Target therapy against molecular markers of EGFR family has been recently used in the treatment protocol of several diseases. However, the role of Her-2/neu in OSCC is a matter of controversy and more studies are required to clarify the role of Her-2/neu in OSCC. We aimed to investigate the role of Her-2/neu in the process of carcinogenesis in oral epithelium as ELP is a premalignant and OSCC is a malignant lesion, but RLP shows no evidence of premalignancy and malignancy.To our Knowledge, this is the first study comparing Her-2/neu expression in erosive lichen planus (ELP), reticular lichen planus (RLP), and oral squamous cell carcinoma (OSCC).
METHODS: 60 samples, including 20 cases of RLP, 20 cases of ELP, and 20 cases of OSCC were evaluated immunohistochemically in this study.
RESULTS: Our findings showed that there was not a significant increase in Her-2/neu expression from RLP to ELP and from ELP to OSCC. Therefore, Her-2/neu had no role in differentiating between RLP, ELP and OSCC and this protein does not contribute to the process of carcinogenesis in the oral epithelium.
CONCLUSION: The lack of Her-2/neu overexpression indicates that molecular targeting of Her-2/neu protein is not recommended as an adjuvant therapy in OSCC and OLP.

Entities:  

Keywords:  Her-2/neu; Immunohistochemistry; Lichen planus; Oral; Squamous cell carcinoma

Year:  2015        PMID: 26793611      PMCID: PMC4708036          DOI: 10.15171/apb.2015.088

Source DB:  PubMed          Journal:  Adv Pharm Bull        ISSN: 2228-5881


  13 in total

1.  Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members.

Authors:  W Xia; Y K Lau; H Z Zhang; F Y Xiao; D A Johnston; A R Liu; L Li; R L Katz; M C Hung
Journal:  Clin Cancer Res       Date:  1999-12       Impact factor: 12.531

2.  Differential gene expression profiles of whole lesions from patients with oral lichen planus.

Authors:  Xiao-An Tao; Chun-Yang Li; Juan Xia; Xi Yang; Xiao-Hua Chen; Yu-Tao Jian; Bin Cheng
Journal:  J Oral Pathol Med       Date:  2009-03-09       Impact factor: 4.253

3.  Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization.

Authors:  A Lebeau; D Deimling; C Kaltz; A Sendelhofert; A Iff; B Luthardt; M Untch; U Löhrs
Journal:  J Clin Oncol       Date:  2001-01-15       Impact factor: 44.544

4.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Authors:  D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich
Journal:  Science       Date:  1989-05-12       Impact factor: 47.728

5.  HER2/neu expression in head and neck squamous cell carcinoma patients is not significantly elevated.

Authors:  Yasaman Sardari; Soheil Pardis; Azadeh Andisheh Tadbir; Mohammad Javad Ashraf; Mohammad Javad Fattahi; Hooman Ebrahimi; Sara Purshahidi; Bijan Khademi; Marzieh Hamzavi
Journal:  Asian Pac J Cancer Prev       Date:  2012

6.  Up-regulation of EGF receptor and its ligands, AREG, EREG, and HB-EGF in oral lichen planus.

Authors:  Kenichi Kumagai; Tatsuya Horikawa; Akito Gotoh; Shoji Yamane; Hiroyuki Yamada; Hiroshi Kobayashi; Yoshiki Hamada; Satsuki Suzuki; Ryuji Suzuki
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2010-10-16

7.  Studies of the serum HER-2/neu and squamous cell carcinoma-related antigen expression in patients with oral squamous cell carcinoma.

Authors:  Chung-Ho Chen; Tsung Lin Tsai; Yi-Shin Yang; Chi-Cheng Tsai
Journal:  J Oral Pathol Med       Date:  2007-02       Impact factor: 4.253

8.  Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma.

Authors:  Atif J Khan; Bonnie L King; Benjamin D Smith; Grace L Smith; Michael P DiGiovanna; Darryl Carter; Bruce G Haffty
Journal:  Clin Cancer Res       Date:  2002-02       Impact factor: 12.531

9.  Decreased expression of the p63 related proteins beta-catenin, E-cadherin and EGFR in oral lichen planus.

Authors:  Majid Ebrahimi; Linda Boldrup; Ylva-Britt Wahlin; Philip J Coates; Karin Nylander
Journal:  Oral Oncol       Date:  2007-10-23       Impact factor: 5.337

10.  Her2 expression and gene amplification is rarely detectable in patients with oral squamous cell carcinomas.

Authors:  Henning Hanken; Robert Gaudin; Alexander Gröbe; Meike Fraederich; Wolfgang Eichhorn; Ralf Smeets; Ronald Simon; Guido Sauter; Katharina Grupp; Jacob R Izbicki; Susanne Sehner; Max Heiland; Marco Blessmann
Journal:  J Oral Pathol Med       Date:  2014-03-20       Impact factor: 4.253

View more
  3 in total

1.  Hormone receptors AR, ER, PR and growth factor receptor Her-2 expression in oral squamous cell carcinoma: Correlation with overall survival, disease-free survival and 10-year survival in a high-risk population.

Authors:  Yumna Adnan; Syed Muhammad Adnan Ali; Muhammad Sohail Awan; Romana Idress; Muhammad Ozair Awan; Hasnain Ahmed Farooqui; Hammad Afzal Kayani
Journal:  PLoS One       Date:  2022-05-11       Impact factor: 3.752

2.  Squamous cell carcinoma from oral lichen planus: a case report of a lesion with 28 years of evolution.

Authors:  Wanessa da Silva Silveira; Ezequiel Gregolin Bottezini; Maria Salete Linden; Isadora Rinaldi; Luiz Renato Paranhos; João Paulo de Carli; Micheline Trentin; Pâmela Letícia Dos Santos
Journal:  J Korean Assoc Oral Maxillofac Surg       Date:  2017-12-27

3.  Expression of HER-2/neu in Oral Squamous Cell Carcinoma.

Authors:  Sana Mirza; Naila Hadi; Shahid Pervaiz; Sultan Zeb Khan; Sameer A Mokeem; Tariq Abduljabbar; Nawwaf Al-Hamoudi; Fahim Vohra
Journal:  Asian Pac J Cancer Prev       Date:  2020-05-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.